407 related articles for article (PubMed ID: 28735353)
1. Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.
Reddy ST; Cossey TC; Savitz SI; Grotta JC
Curr Neurol Neurosci Rep; 2017 Sep; 17(9):67. PubMed ID: 28735353
[TBL] [Abstract][Full Text] [Related]
2. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R; Kavtaradze A; Gupta A; Ghosh RK
Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
[TBL] [Abstract][Full Text] [Related]
3. Reversal agents for non-vitamin K antagonist oral anticoagulants.
Levy JH; Douketis J; Weitz JI
Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
[TBL] [Abstract][Full Text] [Related]
4. How can we reverse bleeding in patients on direct oral anticoagulants?
Crowther M; Cuker A
Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
[TBL] [Abstract][Full Text] [Related]
5. Who, when, and how to reverse non-vitamin K oral anticoagulants.
Aronis KN; Hylek EM
J Thromb Thrombolysis; 2016 Feb; 41(2):253-72. PubMed ID: 26627486
[TBL] [Abstract][Full Text] [Related]
6. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Darius H
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
[TBL] [Abstract][Full Text] [Related]
7. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
[TBL] [Abstract][Full Text] [Related]
8. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab.
Hu TY; Vaidya VR; Asirvatham SJ
Vasc Health Risk Manag; 2016; 12():35-44. PubMed ID: 26937198
[TBL] [Abstract][Full Text] [Related]
9. Reversal of direct oral anticoagulants: a practical approach.
Shih AW; Crowther MA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
[TBL] [Abstract][Full Text] [Related]
10. Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience.
Šaňák D; Jakubíček S; Černík D; Herzig R; Kunáš Z; Mikulík R; Ostrý S; Reif M; Rohan V; Tomek A; Veverka T
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2479-2483. PubMed ID: 29807757
[TBL] [Abstract][Full Text] [Related]
11. [Reversal strategies for non-vitamin K antagonist oral anticoagulants].
Larsen FU; Hvas AM; Grove EL
Ugeskr Laeger; 2016 Oct; 178(40):. PubMed ID: 27697119
[TBL] [Abstract][Full Text] [Related]
12. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
[TBL] [Abstract][Full Text] [Related]
13. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
Tireli D; He J; Nordling MM; Wienecke T
J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
[TBL] [Abstract][Full Text] [Related]
14. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
Boda Z
Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic Reversal of Direct Oral Anticoagulants.
Farina N; Miller JT
Crit Care Nurs Q; 2018; 41(2):121-128. PubMed ID: 29494368
[TBL] [Abstract][Full Text] [Related]
16. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
Huisman MV; Fanikos J
Am J Emerg Med; 2016 Nov; 34(11S):46-51. PubMed ID: 27697438
[TBL] [Abstract][Full Text] [Related]
17. Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options.
Ansell JE
Am J Cardiovasc Drugs; 2016 Jun; 16(3):163-70. PubMed ID: 26872887
[TBL] [Abstract][Full Text] [Related]
18. Non-vitamin K antagonist oral anticoagulant reversal: hope is on the horizon.
Yorkgitis BK
Am J Surg; 2016 Jul; 212(1):160-4. PubMed ID: 27182049
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants.
Andresen K; Atar D; Gjertsen E; Ghanima W; Roseth S; Johansen OE
Scand Cardiovasc J; 2018 Jun; 52(3):156-162. PubMed ID: 29569500
[TBL] [Abstract][Full Text] [Related]
20. Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.
Husted S; Verheugt FW; Comuth WJ
Drug Saf; 2016 Jan; 39(1):5-13. PubMed ID: 26519420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
